CXCL11 and neoplasm: Studies show that intratumoral administration of a CXCL11-armed tumour selective vaccinia OV increases tumour-specific CTLs and granzyme B production, while reducing immunosuppressive cytokines in the TME of a syngeneic mouse mesothelioma model, leading to enhanced cytotoxic activities of CTLs (180).